Compare EXAS & ZBH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EXAS | ZBH |
|---|---|---|
| Founded | 1995 | 1927 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.7B | 19.5B |
| IPO Year | 2000 | 2001 |
| Metric | EXAS | ZBH |
|---|---|---|
| Price | $103.89 | $90.19 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 17 | 19 |
| Target Price | $86.62 | ★ $105.17 |
| AVG Volume (30 Days) | 1.8M | ★ 1.8M |
| Earning Date | 04-30-2026 | 05-04-2026 |
| Dividend Yield | N/A | ★ 1.08% |
| EPS Growth | ★ 80.32 | N/A |
| EPS | N/A | ★ 3.55 |
| Revenue | $4,144,000.00 | ★ $8,231,500,000.00 |
| Revenue This Year | $15.37 | $4.93 |
| Revenue Next Year | $12.41 | $3.72 |
| P/E Ratio | ★ N/A | $25.16 |
| Revenue Growth | N/A | ★ 7.20 |
| 52 Week Low | $38.88 | $84.59 |
| 52 Week High | $104.02 | $114.44 |
| Indicator | EXAS | ZBH |
|---|---|---|
| Relative Strength Index (RSI) | 61.72 | 39.54 |
| Support Level | $103.10 | $89.38 |
| Resistance Level | N/A | $96.45 |
| Average True Range (ATR) | 0.31 | 2.64 |
| MACD | -0.03 | -0.87 |
| Stochastic Oscillator | 86.96 | 13.83 |
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.